NFX.L

Nuformix plc
Nuformix PLC - Result of General Meeting
4th November 2024, 10:17
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8241K
Nuformix PLC
04 November 2024
 

4 November 2024

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Result of General Meeting

 

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that at the General Meeting of the Company held earlier today all resolutions put to shareholders were duly passed and approved by way of a show of hands.  The proxies received ahead of the General Meeting, are reported below:

 

 

Resolution

Ordinary/ Special

For

 

Against

 

Total votes cast




No. of votes

%

No. of votes

%


1

Subdivision of the ordinary shares

 

Ordinary

164,225,020

98.00%

3,356,013

2.00%

167,581,033

2

To authorise the directors to allot shares

 

Ordinary

163,856,186

97.99%

3,361,741

2.01%

167,217,927

3

To authorise the directors to disapply pre-emption rights

 

Special

163,856,186

98.04%

3,273,557

1.96%

167,129,743

4

Amendment of the Company's Articles of Association

 

Special

163,856,186

98.04%

3,273,557

1.96%

167,129,743

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

 

Full details of the Resolutions are contained in the Notice of General Meeting which is available, appended to the Prospectus, on the Company's website at: https://nuformix.com/document-center/

 

Following the passing of the Resolutions at the General Meeting, the expected timetable of events remains the same as documented in the Prospectus and is as follows:

 

2024

Record Date for the Capital Reorganisation

6.00 p.m. on 4 November

Admission of New Ordinary Shares effective and commencement of dealing

8.00 a.m. on 5 November

 

Expected date for CREST accounts to be credited

5 November

Despatch of definitive certificates (where applicable) expected by no later than

11 November

 

 

Admission and Total Voting Rights

 

An application has been made to the London Stock Exchange for the 600,000,000 New Ordinary Shares, to be issued pursuant to the conditional £300,000 fundraise announced on 20 September 2024, to be admitted to the equity shares (transition) category of the Financial Conduct Authority's Official List and to trading on the Main Market of the London Stock Exchange ("Admission").  It is expected that Admission and unconditional dealings in the New Ordinary Shares will commence on the London Stock Exchange at 8.00 a.m. on 5 November 2024.

 

Following Admission of the New Ordinary Shares, the total number of Ordinary Shares in issue will be 1,419,309,368, each with one voting right.  The Company does not hold any rights in treasury.  The total voting rights figure is therefore 1,419,309,368 and can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change of their interest in, the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

 

Terms used in this announcement shall, unless the context otherwise requires, be as defined in the Prospectus published by the Company on 16 October 2024.

 

Enquiries:

 

Nuformix plc

 

Dr Dan Gooding, Executive Director

 

Via IFC Advisory

 

CMC Markets


Douglas Crippen

+44 (0) 20 3003 8632



IFC Advisory Limited


Tim Metcalfe

Zach Cohen

+44 (0) 20 3934 6630

nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities.  Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMMZMGMGDVGDZM]]>
TwitterFacebookLinkedIn